ALB and diabetes mellitus: Potential improvements include integrating comprehensive immunological parameters (e.g., CD19, CD56 cell counts, and inflammatory markers), incorporating sensitive diabetes-related indicators (e.g., glycated albumin), and accounting for medication adherence and treatment history.